Population
In vitro models using plasma (normal and prothrombin-deficient) and purified proteases
Design
Preclinical
Authors
Loading...
HCII's restricted thrombin specificity supports dermatan sulfate's selective action in preclinical models; leaves open human translation and clinical relevance.
Heparin cofactor II has highly restricted protease specificity, suggesting the anticoagulant effect of dermatan sulfate is solely due to thrombin inhibition by HCII.
Parker et al. (1985) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: